Kommuniké från extra bolagsstämma i Ortoma AB

Publicerat 17 Dec, 2020

Den 17 december 2020 hölls bolagstämma i Ortoma AB. Vid stämman fattades följande beslut:

Val av revisor

Mazars valdes som bolagets revisionsbolag. Mazars har utsett David Johansson som huvudansvarig revisor.


Göteborg den 17 december 2020

Ortoma AB


Denna information är sådan som Ortoma är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning (EU nr 596/2014). Informationen lämnades, genom angiven kontaktpersons försorg, för offentliggörande 2020-12-17 12:04 CET.

About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Spotlight Stock Market.